ASX Announcements
Company Administration - Other
Market Sensitive
Appendix 4D and December 2024 Half Year Accounts
Half Yearly Report, Half Year Audit Review, Half Year Directors' Statement, Half Year Accounts, Half Year Directors' Report
Top20 quoted option holders and distribution schedule
Top 20 shareholders
Change of Director’s Interest Notice
December 2016
Property developer Lang Walker's biotechnology investment secrets
Lang Walker says he's yet to have his biggest success, but his biggest failure was the $10m he lost on QRxPharma.
January 2015
Essential services look set for healthy returns this year
Depending on the theme investors wish to tap into there is good value among small cap healthcare and services companies. In what is shaping up as a tricky year on the sharemarket companies exposed to essential services are likely to be well supported.
‘Patient capital’ is best medicine for biotech sector
A group of wealthy backers including billionaire property developer Lang Walker are hoping that Richard Treagus, who is now leading Neuren Pharmaceuticals, is the secret to success in biotechnology investing.
November 2014
Acrux gets good news in Europe
Acrux investors have taken heart from a ruling by the European drug regulator that testosterone therapy does not increase the risk of cardiac problems.
Acrux (ACR)
Morningstar cut Acrux to “accumulate” from “buy” with a “very high” fair value uncertainty and a $2 fair value price.
October 2014
Falling iron price lures investors from traditional market darlings
There is a range of trends grabbing investors’ attentions that have not been seen for some time. The big banks and miners have long been market darlings, but the falling iron ore price and dollar, as well as speculation the regulators will act to curb the boom in property markets, has prompted a substantial correction in these stocks. Volatility in equities markets, and in the dollar, has also risen sharply. Given this background, it’s likely to be a very interesting run up to Christmas in financial markets.
September 2014
Acrux (ACR)
Morningstar recommends a ‘hold’ position on drug company Acrux, with a high fair value uncertainty on its price. The fair value expectation at present is $2.00.
August 2014
ASX200 shorts position slides: CBA
CBA notes the aggregate shorts position eased to 1.23 per cent of the S&P/ASX200 market capitalisation between 15 and 22 August, reversing the previous week’s increase.
Going short may signal a Waterloo
Philip Baker | Short selling can be a risky strategy. But it doesn’t stop investors from looking for overpriced stocks to sell rather than spend their time combing the list for underpriced stocks to buy.
July 2014
Lang Walker claims big name in biotech board fight
Billionaire property developer Lang Walker’s quest to shake up the board of troubled pain drug developer QRxPharma has been more successful than first imagined, following the resignation of chairman Peter Farrell and three directors ahead of Wednesday’s shareholder meeting.
Credit Suisse sounds warning on heavily shorted stocks
Beware heavily shorted stocks heading into reporting season, Credit Suisse’s quantitative analysts have warned clients, with crowded trades prone to falling apart on better-than-expected news.
Acrux faces testosterone challenges
The testosterone replacement therapy market faces a gauntlet of challenges that could crush investors in biotechnology company Acrux.
June 2014
Farrell calls Walker naive in QRxPharma battle
QRxPharma chairman Peter Farrell says the embattled pain drug developer has faltered due to the US regulator’s shifted goalposts and that disgruntled shareholder Lang Walker is naive if he thinks he can do better.
Caution ahead of ECB meet sees ASX slide
Proof that Australia’s economy performed better than expected in the first quarter of 2014 was not enough to buoy the sharemarket as stocks sold off, with global investors cautious ahead of a key ECB meeting.
QrXPharma board faces spill as it mulls quitting
Pain drug developer QrXPharma has urged shareholders to vote against a spill of two directors proposed by investor Lang Walker, while also flagging it was considering giving up on its technology.
May 2014
Lang Walker pushes for QrXPharma board upheaval
Fresh from a multimillion-dollar loss on his investment in pain drug developer QrXPharma, rich list property developer Lang Walker is trying to eject founder Gary Pace and chairman Peter Farrell.
Rich list names hurt by cruel April for biotech stocks
In April almost $1 billion was wiped from the combined market value of four well-regarded companies: Acrux, Mesoblast, QrXPharma and Prana Biotechnology, dragging down equally well known names such as Waislitz and Liberman.
April 2014
Acrux falls 15pc on sales warning
Drug delivery company Acrux has warned it is at risk of missing its next milestone payment from distributor Eli Lilly as concerns about a potential link between testosterone replacement therapy and heart failure hurt US sales.
How to pick the next hot biotechnology stock
It’s a harsh but true assessment that many investors don’t understand biotechnology. So what hope is there for retail investors to profit from the next wonder drug?
March 2014
Acrux Ltd (ACR)
Morningstar has a “hold” recommendation on Acrux after analysts met with management and reviewed growth assumptions for the company’s products.